Published in Breast Cancer (Auckl) on August 17, 2016
Relationship between LINC00341 expression and cancer prognosis. Oncotarget (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 22.64
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
Oxidative stress shortens telomeres. Trends Biochem Sci (2002) 9.48
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 8.74
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol (2003) 7.02
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell (1999) 5.93
Aneuploidy and cancer. Nature (2004) 5.61
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med (1995) 5.27
Estrogen and the risk of breast cancer. N Engl J Med (2001) 4.39
Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst (2004) 4.24
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer (1985) 3.92
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 3.89
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature (2001) 3.58
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (1996) 3.54
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res (2000) 3.24
Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc Natl Acad Sci U S A (1984) 3.22
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells (1998) 3.13
Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med (1994) 3.09
Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res (2000) 3.06
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res (2011) 3.02
COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer (2000) 2.94
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst (2000) 2.82
Cyclin D1 protein expression and function in human breast cancer. Int J Cancer (1994) 2.81
Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med (1995) 2.74
Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev (1999) 2.74
High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A (2000) 2.70
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res (2004) 2.67
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
Estrogens as endogenous genotoxic agents--DNA adducts and mutations. J Natl Cancer Inst Monogr (2000) 2.55
Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol (1999) 2.52
Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev (2000) 2.47
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol (2012) 2.34
Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol (1999) 2.32
Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res (2004) 2.29
Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys (2003) 2.28
Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer Res (2009) 2.28
Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A (1991) 2.27
Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem (1997) 2.27
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res (2002) 2.25
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res (2001) 2.21
Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med (2000) 2.19
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18
Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res (2001) 2.18
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer (2003) 2.18
Loss of heterozygosity induced by a chromosomal double-strand break. Proc Natl Acad Sci U S A (1997) 2.17
Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet (2001) 2.16
Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res (1995) 2.04
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res (1992) 2.00
Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res (2001) 1.95
Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res (2005) 1.93
Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem (2006) 1.93
Reactive oxygen species (ROS)--induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res (2011) 1.90
Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene (2001) 1.89
Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev (2014) 1.86
Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol (2005) 1.86
17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol (2000) 1.83
Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat (2009) 1.83
Cyclin E, a potential prognostic marker for breast cancer. Cancer Res (1994) 1.82
Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res (1997) 1.79
Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst (1998) 1.77
Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics (2004) 1.76
The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia (1998) 1.75
c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol (1996) 1.75
Telomeres and chromosome instability. DNA Repair (Amst) (2006) 1.70
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst (2001) 1.68
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol (2003) 1.66
Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res (2009) 1.65
Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol (2003) 1.59
The epigenetics of breast cancer. Mol Oncol (2010) 1.57
Prognostic importance of survivin in breast cancer. Br J Cancer (2003) 1.56
Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res (2004) 1.55
Significant role for p16INK4a in p53-independent telomere-directed senescence. Curr Biol (2004) 1.55
Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. Proc Natl Acad Sci U S A (2000) 1.54
Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res (2001) 1.52
Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res (2001) 1.51
Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res (2001) 1.51
Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int J Cancer (2008) 1.51
Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep (2012) 1.51
Estrogen and progesterone receptors in the normal female breast. Cancer Res (1991) 1.50
Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol (1999) 1.50
Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet (2008) 1.47
Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies. Cancer (2015) 1.47
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res (2010) 1.46
Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene (2010) 1.46
Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res (2009) 1.45
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol (2017) 1.38
An Improved Breast Epithelial Sampling Method for Molecular Profiling and Biomarker Analysis in Women at Risk for Breast Cancer. Breast Cancer (Auckl) (2015) 0.76